University of Leeds

How Well Does Ultrasound-assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? - Exploratory Results from a Phase 3b Study (2022) D'Agostino MA, Conaghan PG, Gaillez C, Naredo E, Mandl P, Carron P, Senolt L, et al. Conference contribution CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research (2022) Kotecha D, Asselbergs FW, Achenbach S, Anker SD, Atar D, Baigent C, Banerjee A, et al. Journal article Gender equity in academic rheumatology, current status and potential for improvement: a cross-sectional study to inform an EULAR task force (2022) Ovseiko P, Gossec L, Andreoli L, Kiltz U, Van Mens L, Hassan N, Van Der Leeden M, et al. Journal article Consensus statements on complete mesocolic excision for right-sided colon cancer—technical steps and training implications (2022) Tejedor P, Francis N, Jayne D, Hohenberger W, Khan J Journal article European Society of Cardiology: cardiovascular disease statistics 2021: Executive Summary (2022) Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, Gale CP, et al. Journal article ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma (2022) Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, Cowan A, et al. Journal article PREDICTING OUTCOMES IN SYSTEMIC SCLEROSIS: STRATIFICATION BY AUTO-ANTIBODIES OUTPERFORMS CUTANEOUS SUBSETTING IN THE EUSTAR COHORT (2022) Elhai M, Boubaya M, Sritharan N, Balbir-Gurman A, Siegert E, Hachulla E, De Vries-Bouwstra J, et al. Conference contribution CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH SYSTEMIC SCLEROSIS SINE SCLERODERMA: DATA FROM THE INTERNATIONAL EUSTAR DATABASE. (2022) Lescoat A, Huang S, Carreira P, Siegert E, De Vries-Bouwstra J, Distler J, Smith V, et al. Conference contribution REDUCED JOINT SYNOVITIS ASSESSMENT VERSUS THE GLOBAL EULAR OMERACT SYNOVITIS SCORE (GLOESS) TO PREDICT THE RESPONSE TO SECUKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: EXPLORATORY RESULTS FROM THE ULTIMATE TRIAL (2022) D'Agostino MA, Boers M, Schett G, Conaghan PG, Naredo E, Mandl P, Carron P, et al. Conference contribution GUSELKUMAB MAINTAINS RESOLUTION OF DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS THROUGH 2 YEARS FROM A PHASE 3 STUDY (2022) Rahman P, Mcinnes I, Deodhar A, Schett G, Mease PJ, Shawi M, Cua D, et al. Conference contribution